Published: 2019 April 09
Updated : 2022 October 01

Cancer Immunotherapy Market

180 pages
Report Summary
Table of Contents
List of Tables& Figures

Cancer Immunotherapy Market is segmented by Product Type(Monoclonal Antibodies, Cancer Vaccines, Immune Checkpoint Inhibitors, Others)by Cancer Type(Lung Cancer, Breast cancer, Head and neck cancer, Melanoma, Colorectal cancer, Ovarian cancer, Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029.

Cancer Immunotherapy Market Size Share Drivers Outlook

The global cancer immunotherapy market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 7.1% during the forecast period (2022-2029). Cancer immunotherapy is a type of cancer treatment that helps the immune system fight cancer. The immune system helps the body fight infections and other diseases. It is made up of white blood cells and organs and tissues of the lymph system. Immunotherapy can treat many different types of cancer. It can be used alone or in combination with chemotherapy and/or other cancer treatments.

Global Cancer Immunotherapy Market-Market Dynamics

The rise in prevalence of cancers drives the global cancer immunotherapy market growth, due to growing demand for the monoclonal antibodies, robust product pipelines of the companies in cancer immunotherapy, and increasing investments in the R & D for the development of the novel drugs are some of the major factors driving the growth and size of the cancer immunotherapy market. Rising R&D activities and increasing the effectiveness and accuracy of newer therapies will drive market growth.

The rising R&D activities mainly drive the cancer immunotherapy therapeutics market. For instance, the Breast Cancer Research Foundation (BCRF) is a non-profit organization providing critical funding for cancer research across the globe to fuel advances in tumor biology, genetics, prevention, treatment, metastasis, and survivorship. Also, provides the most reliable, complete, and updated information about breast cancer to create awareness among patients. The increasing incidence of cancer is found that has been a significant factor in the growth of the cancer immunotherapy market.

According to the National Clinical Trials (NCT) Registry, as of 8th September 2020, there are more than 1,000 ongoing clinical trials worldwide across different phases of development in the treatment of cancer with immune-based therapies moreover, as these therapies are in development if trials show can be expected for positive cancer outcomes shortly new effective immuno-therapies.

Cancer immunotherapy is found to play a vital role in maintaining the immune system, and it targets the infectious agents that may cause cancer through the production of antibodies. Cancer Immunotherapy is considered a new therapy. However, it has shown great potential over the past few years. Also, with the massive burden of cancer cases and side effects of the current therapies, the market is expected to grow at a high growth rate during the forecast period. 

The high cost of treatment will hamper the growth of the market

However, the cost of immunotherapies varies among different tumor types. The pembrolizumab incurred one-year per-patient costs of $145,010 and $130,511 for the treatment of MM and NSCLC, respectively, and achieved median progression-free survival (PFS) of 6.3 months for each type of cancer. As per NCBI, the one-year worldwide cost for treating these cancers with pembrolizumab was estimated to be $3.8 billion and $83.9 billion, respectively. Thus, these factors will hamper the market growth in the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has drastically affected buying capacity of hospitals, especially small-scale hospitals and scanning centers. According to an article by Cigna, there have been reductions in hospitalizations for non-elective conditions s that raise the possibility that patients may be deferring necessary elements of clinical care. The clinical trials of the new cancer immunotherapy drugs are kept on hold, as during this crisis the individual is more susceptible to suffering from COVID-19. COVID-friendly cancer treatments, however, are observed to be increased during the course of time and would propel in the coming years. Thus, the COVID-19 pandemic is anticipated to have a negative impact on the cancer immunotherapy market.

Collagen & Gelatin Market Scope



Market CAGR


Segments Covered

 By Product Type, By Cancer Type, By End User, Region, 

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To know more insights into the Market, Get Our Sample Brochure

Segmentation Analysis

The breast cancer segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

Breast cancer is found to be cancer that develops in the breast cells. The signs of breast cancer include a lump in the breast, a change in breast shape, dimpling of the skin, a newly inverted nipple, or a red or scaly patch of skin. According to the (CDC) Centre for Disease Control and Prevention, breast cancer is the most common cancer in women. There is a rising number of breast cancer cases across the globe, driving the market's overall growth. Thus, the increasing urge for effective, lasting breast cancer treatment is necessary.

The rising R&D and awareness about breast cancer are expected to boost the market's overall growth. For instance, the Breast Cancer Research Foundation (BCRF) is a non-profit organization providing critical funding for cancer research across the globe to fuel advances in tumor biology, genetics, prevention, treatment, metastasis, and survivorship. Also, provides the most reliable, complete, and updated information about breast cancer to create awareness among patients.

Regional Insights:

North America region holds the largest market share of the global cancer immunotherapy market

North America is expected to dominate the overall cancer immunotherapy market in the forecast period. The major factors driving the market's growth in North America are developed healthcare infrastructure and increased government initiatives, which offer lucrative reimbursement policies. According to the estimates of the GLOBOCAN in 2020, there were an estimated 2,281,658 new cancer cases diagnosed and 612,390 deaths due to cancer in the United States. The Canadian Cancer Society (CCS) estimated that in 2020, approximately 29,800 Canadians would be diagnosed with lung cancer. Represents 13% of all new cancer cases. About 21,200 Canadians are expected to die from lung cancer. Means 25% of all cancer deaths in 2020. Indicates a significant potential market demand for cancer immunotherapy. The studied market is expected to grow owing to the increasing burden of various types of cancer.

The market players are also focusing on launching new products in the market. For instance, in 2019, the USFDA approved Merck's cancer therapy known as Keytruda, a part of combination therapy for previously untreated patients with the most common type of kidney cancer. Furthermore, various organizations are increasing awareness regarding cancer. Therefore, with the increasing cancer burden and the rising R&D in cancer, the market is expected to experience lucrative growth during the forecast period.

Competitive Landscape Analysis:

The cancer immunotherapy market is a moderately competitive presence of local and global companies. Some of the key players contributing to the market's growth include Amgen Inc., Astellas Pharma, Inc., AstraZeneca, Bayer AG, Bristol-Myers Squibb, Eli Lilly and Co., F. Hoffman La Roche, Merck and Co., Novartis, OSE Immunotherapeutics, among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, contributing to the growth of the Cancer Immunotherapy Market globally. For instance, on 16th April 2021, U.S. Food and Drug Administration approved Opdivo (nivolumab), in combination with certain types of chemotherapy, for the initial treatment of patients with advanced or metastatic gastric cancer gastroesophageal junction cancer, and esophageal adenocarcinoma. The first FDA-approved immunotherapy for the first-line treatment of gastric cancer.

Amgen Inc.

Overview: Amgen Inc. is an independent biotechnology medicines company that discovers, develops, manufactures, and markets medicines for grievous illnesses. The Company focuses on human therapeutics and innovating novel drugs based on cellular and molecular biology.

Product Portfolio: BLINCYTO (Blinatumomab):  BLINCYTO is the first BiTE antibody construct and the first single-agent immunotherapy approved by the U.S. Food and Drug Administration (FDA). BLINCYTO was granted breakthrough therapy and priority review designations by the FDA and is now supported in the U.S. for the treatment of Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). 

The global cancer immunotherapy market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 205 (approximate) pages.

Trending Topics

Cancer CDK Inhibitors Market

Kidney Cancer and Renal Cell Carcinoma Drugs Market

Radiodermatitis Market


Frequently Asked Questions

What is the Projected CAGR value of the Cancer Immunotherapy Market?

Cancer Immunotherapy Market is expected to grow at a CAGR of 7.1% during the forecasting period 2022-2029.

Which region controlled the global market during 2022-2029?

North America region Controls the Cancer Immunotherapy Market during 2022-2029

Which is the fastest growing region in the Cancer Immunotherapy Market?

Among all regions, Asia Pacific is the fastest growing market share during the forecast period 

Buy this report
Single User
Multiple User
Enterprise User
Proceed to Buy